This page shows the publications co-authored by Massimo Loda and Matthew Freedman.
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51.
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 Apr; 2(4):444-456.
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6.
A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine. 2015 Dec; 2(12):1957-64.
Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.